Heart failure in haemoglobinopathies: pathophysiology, clinical phenotypes, and management
- 20 December 2016
- journal article
- review article
- Published by Wiley in European Journal of Heart Failure
- Vol. 19 (4), 479-489
- https://doi.org/10.1002/ejhf.708
Abstract
Hereditary haemoglobinopathies, mainly beta-thalassemia and sickle cell disease, constitute the most common monogenic disorders in humans, and although once geographically confined, they are currently globally distributed. They are demanding clinical entities that require multidisciplinary medical management. Despite their genotypic and phenotypic heterogeneity, the haemoglobinopathies share several similarities in pathophysiology, clinical manifestations, therapeutic requirements, and complications, among which heart failure (HF) represents a leading cause of mortality and morbidity. However, haemoglobinopathies have generally been addressed in a rather fragmentary manner. A unifying approach focusing on the underlying similarities of HF attributes in the two main entities might contribute to their better understanding, characterization, and management. In the present review, we attempt such an approach to the pathophysiology, clinical phenotypes, and management of HF in haemoglobinopathies.Keywords
This publication has 89 references indexed in Scilit:
- Cardiovascular Function and Treatment in β-Thalassemia MajorCirculation, 2013
- Pulmonary Hypertension Associated With HemoglobinopathiesCirculation, 2011
- Sickle-cell diseaseThe Lancet, 2010
- β-Thalassemia CardiomyopathyCirculation: Heart Failure, 2010
- Pulmonary Complications of Sickle Cell DiseaseThe New England Journal of Medicine, 2008
- Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 2008
- β-ThalassemiaThe New England Journal of Medicine, 2005
- Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia majorBlood, 2004
- Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell DiseaseThe New England Journal of Medicine, 2004
- SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJORThe Lancet, 1989